Travere Therapeutics is a biopharmaceutical company that focuses on developing and delivering life-changing therapies to people living with rare diseases.
This could be useful if you’re looking for information on how to compare prices with competitors.
Location: United States, California, San Diego
Employees: 201-500
Phone: +1 888-969-7879
Total raised: $275M
Founded date: 2020
Investors 1
| Date | Name | Website |
| 04.07.2022 | Internatio... | ibtplc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.03.2022 | - | $275M | - |
Mentions in press and media 21
| Date | Title | Description | Source |
| 29.04.2024 | Travere Therapeutics to Report First Quarter 2024 Financial ... | SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) toda... | einpresswi... |
| 24.04.2024 | CSL Vifor and Travere Therapeutics Announce European Commiss... | First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe C... | en.prnasia... |
| 04.04.2024 | Travere Therapeutics to Present Abstracts at the Society for... | Posters to be presented highlighting research investigating pegtibatinase as the first potential dis... | einpresswi... |
| 13.03.2024 | Travere Therapeutics Reports Inducement Grants Under Nasdaq ... | - | globenewsw... |
| 13.03.2024 | Travere Therapeutics Reports Inducement Grants Under Nasdaq ... | SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announ... | einpresswi... |
| 26.02.2024 | Travere Therapeutics to Present at Upcoming Investor Confere... | SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announc... | einpresswi... |
| 15.02.2024 | Travere Therapeutics Reports Fourth Quarter and Full Year 20... | Received 459 new patient start forms (PSFs) for FILSPARI® (sparsentan) in Q4 2023; Total of 1,452 PS... | einpresswi... |
| 01.02.2024 | Travere Therapeutics to Present at the Guggenheim 6th Annual... | SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announc... | einpresswi... |
| 08.01.2024 | Travere Therapeutics Provides Corporate Update and 2024 Outl... | Received 459 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2023; preli... | einpresswi... |
| 21.11.2023 | Travere Therapeutics to Present at the 6th Annual Evercore I... | SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announc... | einpresswi... |
Show more